AbbVie, Inc. (ABBV) is currently at $165.64, down $4.00 or 2.36% --Would be lowest close since July 3, 2024, when it closed at $163.84 --Currently down eight consecutive days; down 17.87% over this ...
Zacks.com on MSN19h
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?AbbVie’s ABBV stock declined almost 11% in the past month, mainly due to a recent pipeline setback. In November, AbbVie ...
AbbVie said two trials investigating emraclidine as a once-daily, oral monotherapy treatment for adults with schizophrenia ...
At the start of 2023, U.S. patent exclusivity expired for the blockbuster drug Humira, AbbVie's chief cash cow. During the 20 ...
Wolfe Research initiated coverage of AbbVie (ABBV) with an Outperform rating and $205 price target The firm noted that AbbVie sounded ...
Dividend stocks are attractive for their steady income, stability, and growth potential, especially amid low interest rates ...
WINCHESTER, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a biopharmaceutical company advancing novel therapeutics to transform the care of serious diseases, today reported ...
Dividend growth stocks offer a unique blend of reliability and growth potential, making them an ideal choice for long-term ...
Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD), a GI-focused healthcare company, today reported its third quarter 2024 results and recent business performance. "LINZESS ...
REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and recent operational highlights for the third quarter ended September 30, 2024.
Shares of AbbVie Inc. ABBV sank 0.16% to $203.55 Friday, on what proved to be an all-around positive trading session for the stock market, with the S&P 500 Index SPX rising 0.41% to 5,728.80 and ...
GSK acquired an experimental therapy from Chimagen Biosciences, paying $300 million upfront for the “T-cell engager” therapy, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback